- Preclinical data for multi-antibody anticancer candidate 스피드 바카라/ABP-102 revealed at the world's largest immuno-oncology conference
- High anticancer efficacy and low toxicity demonstrated, indicating potential as a new treatment option for ENHERTU-resistant patients
- Recognized for originality and therapeutic impact, selected as a ‘Top 150’ study among over 1,300 conference abstracts
- "Building on preclinical results, we aim to submit an IND this year and develop a 'best-in-class' novel drug"
[by Lee, Young Sung] Celltrion announced on November 5 that it will present preclinical data for its multi-antibody drug candidate, CT-P72/ABP-102, at the American Society for Immunotherapy of Cancer (SITC 2025), the world's largest immuno-oncology academic conference, taking place in Maryland, USA, from November 5 to 9 (local time).
스피드 바카라/ABP-102 is a multi-antibody immuno-oncology therapy co-developed by Celltrion and Abpro. The candidate employs a T-cell engager (TCE) mechanism, which connects T cells, a key component of the immune system, to cancer cells expressing the HER2 (human epidermal growth factor receptor 2) protein, an important regulator of cellular growth, thereby eliminating cancer cells.
Preclinical studies of 스피드 바카라/ABP-102 demonstrated potent anti-tumor efficacy specifically against HER2-high-expressing tumors in a dual xenograft mouse model implanted simultaneously with both high- and low-HER2-expressing cell lines. In addition, toxicology studies in non-human primates confirmed the candidate’s favorable safety profile, with no significant adverse effects observed even at doses as high as 80mg/kg.
The selective anti-tumor efficacy and favorable safety profile of 스피드 바카라/ABP-102 against HER2-high-expressing tumors can be attributed to its structural design. 스피드 바카라/ABP-102 is engineered to reduce T-cell avidity toward normal cells with low HER2 expression while optimizing binding affinity to selectively target cancer cells with high HER2 expression. Moreover, the affinity for the CD3 protein on T cells was successfully modulated to achieve optimal T cell activation.
This structural optimization led to reduced toxicity and demonstrated superiority in the therapeutic index (TI), the ratio between a drug’s toxic dose and therapeutically effective dose, when compared with other similar-mechanism therapies (HER2-targeting TCE drugs). Based on these findings, Celltrion aims to advance 스피드 바카라/ABP-102 as a ‘best-in-class’ novel drug.
In particular, in animal studies evaluating the therapeutic efficacy of 스피드 바카라/ABP-102 against cancer cells resistant to ENHERTU (trastuzumab deruxtecan), a leading HER2-targeting anticancer drug, the candidate exhibited significant tumor growth inhibition, highlighting its potential as a novel treatment option compared to existing therapies.
Furthermore, Celltrion's preclinical research on 스피드 바카라/ABP-102 was highly evaluated for its novelty and contribution to advancing the field of immunotherapy. The study was selected as one of the ‘TOP 150’ abstracts out of more than 1,300 submissions to the academic society, underscoring the scientific excellence and clinical potential of 스피드 바카라/ABP-102. Building on these preclinical findings, Celltrion plans to submit a Phase 1 clinical trial Investigational New Drug (IND) application for 스피드 바카라/ABP-102 to major Korean and international regulatory agencies within the year and subsequently initiate full-scale clinical trials.
"The multi-antibody anticancer drug candidate 스피드 바카라/ABP-102 has demonstrated remarkable efficacy and safety in preclinical studies and has attracted significant attention, as evidenced by its selection as a ‘TOP 150’ study at SITC 2025. We remain committed to successfully advancing clinical trials with the goal of developing this novel therapy as a best-in-class drug that surpasses existing treatments," a Celltrion official stated.